|Table of Contents|

A pilot study on the difference of gut microbiota between patients with lung cancer and healthy controls

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 04
Page:
653-658
Research Field:
Publishing date:

Info

Title:
A pilot study on the difference of gut microbiota between patients with lung cancer and healthy controls
Author(s):
JIAO Qianqian1; YAN Junhong2; WANG Jing1; ZHU Jiwei1; PAN Lei1
1.Department of Respiratory and Critical Care Medicine;2.Department of Ultrasound Medicine，Binzhou Medical University Hospital，Shandong Binzhou 256603，China.
Keywords:
lung cancer; gut microbiota; diversity; species; difference
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.04.011
Abstract:
Objective:To analyze and compare the differences in species richness,community composition and bacterial metabolism of gut microbiota between patients with lung cancer and healthy controls,and to explore the role of gut microbiota in the pathogenesis of lung cancer,in order to provide new strategies for the prevention and treatment of lung cancer.Methods:Patients with lung cancer who came to the department of respiratory and critical care medicine in our hospital from December 2018 to December 2019 were randomly selected as the experimental group (lung cancer group),and their family members were selected as the control group (healthy group).Sequencing technology detected the fecal samples of the two groups of people,analyzed the differences in the Alpha and Beta diversity of the gut microbiota between the two groups,the relative abundance of species and community structureat the phylum and genus levels,and predicted the metabolic function of the flora.Differences in metabolic function between the two groups were analyzed.Results:34 valid samples were obtained in the lung cancer group and 32 valid samples in the control group.The species richness of gut microbiota in patients with lung cancer was lower than that in the healthy group,and the difference was statistically significant (P<0.05).The community diversity of the lung cancer group was lower than that of the healthy group,and the difference was statistically significant (P<0.05).The community structure of gut microbiota in lung cancer group was different from that of the healthy group.The flora abundance of potential pathogenic bacteria was relatively increased.The relative abundance of beneficial bacteria of chain fatty acids such as firmicutes and bacteroidetes decreased,and the difference was statistically significant (P<0.05).Compared with the healthy group,the lung cancer group had higher relative abundances in functions such as glucose metabolism,amino acid metabolism,and exogenous biodegradation (P=0.009,0.033,0.016),while the relative abundances of cofactor and vitamin metabolism functions decreased (P=0.002).Subgroup analysis showed that the differences inthe abundance of some gut microbiota at the phylum and genus levels was related to the type and gender of patients with lung cancer.Conclusion:The gut microbiota of lung cancer patients and their healthy family members are different in species richness,community composition and flora metabolic function.The abundance of potential pathogenic bacteria is relatively increased,and the relative abundance of beneficial bacteria that can produce short-chain fatty acids is decreased.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2022 ［J］.CA Cancer J Clin,2022,72(1):7-33.
［3］ZOU XL,WU JJ,YE HX,et al.Associations between gut microbiota and asthma endotypes:A cross-sectional study in South China based on patients with newly diagnosed asthma ［J］.J Asthma Allergy,2021,14:981-992.
［4］WOODALL CA,MCGEOCH LJ,HAY AD,et al.Respiratory tract infections and gut microbiome modifications:A systematic review ［J］.PLoS One,2022,17(1):e0262057.
［5］FARSI Y,TAHVILDARI A,ARBABI M,et al.Diagnostic,prognostic,and therapeutic roles of gut microbiota in COVID-19:A comprehensive systematic review［J］.Front Cell Infect Microbiol,2022,12:804644.
［6］Chinese Medical A,Oncology Society of Chinese Medical A,Chinese Medical Association Publishing H.Chinese medical association guidelines for clinical diagnosis and treatment of lung cancer (Edition 2018)［J］.Chin J Oncol,2018,40(12):935-964.
［7］WANG RF,CAO WW,CERNIGLIA CE.PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples ［J］.Appl Environ Microbiol,1996,62(4):1242-1247.
［8］MAGOC T,SALZBERG SL.FLASH:fast length adjustment of short reads to improve genome assemblies ［J］.Bioinformatics,2011,27(21):2957-2963.
［9］CAPORASO JG,KUCZYNSKI J,STOMBAUGH J,et al.QIIME allows analysis of high-throughput community sequencing data ［J］.Nat Methods,2010,7(5):335-336.
［10］LI M,WANG B,ZHANG M,et al.Symbiotic gut microbes modulate human metabolic phenotypes ［J］.Proc Natl Acad Sci USA,2008,105(6):2117-2122.
［11］NAGASAKA M,SEXTON R,ALHASAN R,et al.Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review ［J］.Crit Rev Oncol Hematol,2020,145:102841.
［12］TRIVEDI R,BARVE K.Gut microbiome a promising target for management of respiratory diseases ［J］.Biochem J,2020,477(14):2679-2696.
［13］MJOSBERG J,RAO A.Lung inflammation originating in the gut ［J］.Science,2018,359(6371):36-37.
［14］CARBONE C,PIRO G,DI NOIA V,et al.Lung and gut microbiota as potential hidden driver of immunotherapy efficacy in lung cancer［J］.Mediators Inflamm,2019,2019:7652014.
［15］KIM K,KWON O,RYU TY,et al.Propionate of a microbiota metabolite induces cell apoptosis and cell cycle arrest in lung cancer ［J］.Mol Med Rep,2019,20(2):1569-1574.
［16］ZITVOGEL L,DAILLERE R,ROBERTI MP,et al.Anticancer effects of the microbiome and its products ［J］.Nat Rev Microbiol,2017,15(8):465-478.
［17］SUN M,WU W,CHEN L,et al.Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis ［J］.Nat Commun,2018,9(1):3555.

Memo

Memo:
山东省医药卫生科技发展计划项目资助（编号：2017WS366）;滨州医学院科研启动基金（编号：BY2017KYQD14）
Last Update: 1900-01-01